liver cancer cannot be resected
Conditions
Interventions
Atrilizumab combined with bevacizumab:NA
Sponsors
the First Affiliated Hospital of Army Medical University,PLA
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.18-75 years old, gender unlimited; 2. Histologically, pathologically, or clinically confirmed inoperable primary liver cancer with at least one measurable lesion; 3. Treatment with Atrilizumab combined with bevacizumab; 4. Patients with an ECOG score of 0-1 were included in the evaluation according to the activity status scale developed by the Eastern Cooperative Oncology Group (ECOG). 5, Child-Pugh liver function A or B grade.
Exclusion criteria
Exclusion criteria: (1) Complicated with other serious diseases, including serious cardiovascular and cerebrovascular diseases, serious liver function injury (bilirubin is 2 times higher than the reference value, transaminase is 5 times higher than the reference value), serious renal function injury (eGFR<45 ml/min), and blood diseases; 2. Combined with other malignant tumors, except cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (cancer in situ) and T1 (tumor infiltrating basal membrane)]; 3, combined with active infectious diseases, such as acute viral hepatitis; Have any active autoimmune disease or a history of autoimmune disease; 4. Pregnant or lactating women; 5. Incomplete data, including baseline data, follow-up data or outcome data, could not satisfy the data analysis of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Surivial;time to progress;Disease control rate; | — |
Countries
China
Contacts
Public ContactZhang Hui
the First Affiliated Hospital of Army Medical University,PLA
Outcome results
None listed